Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Organigram Global Inc.

OGI Nasdaq Pharmaceutical Preparations Financials FY2018โ€“FY2025

Revenue Total sales reported in the income statement.
$185M
vs prior year
Operating margin Operating income as a share of revenue.
โˆ’5.9%
Net income Profit after all expenses, interest and tax.
โˆ’$17.7M
Free cash flow Cash from operations minus capital spending.
โˆ’$17.6M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โˆ’4.5%
Market cap Last close times the latest diluted share count, so it is approximate.
โ€”
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$0.14 EPS (TTM)

What Organigram Global Inc. does

No business description yet.

Legal name
ORGANIGRAM GLOBAL INC.
Fiscal year ends
September 30, 2025
Latest annual report
40-F ยท Dec 16, 2025
Accession ยท CIK
0001628280-25-057233
0001620737

Revenue and margins

Organigram Global Inc. had $185M of revenue in fiscal 2025.

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$17.6M in fiscal 2025, โˆ’9.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Organigram Global Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 0.0%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Organigram Global Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY20FY21FY22FY24FY25
Cash and short-term investments โ€”โ€”โ€”$98.1M$60.0M
Debt incl. finance leases $88.2M$0.2M$0.2M$0.0M$0.0M
Debt / equity 0.4x0.0x0.0x0.0x0.0x
Interest coverage โˆ’24.2xโˆ’31.0xโˆ’100.6xโ€”โ€”
Current ratio 5.9x9.9x4.0x4.9x2.3x
Quick ratio 3.6x8.5x3.1x3.7x1.4x
Total assets $333M$440M$440M$302M$404M
Total liabilities $104M$59.0M$52.7M$75.4M$153M
Shareholders' equity $229M$381M$388M$226M$251M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โˆ’$98.1Mโˆ’$60.0M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY18FY19FY20FY21FY22FY25
Net income is positive โœ“ โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ• โœ• โœ“ โœ“ โ€”
Cash from operations exceeds net income โœ• โœ• โœ“ โœ“ โœ• โœ“
Debt fell relative to assets โ€” โœ• โœ• โœ“ โœ“ โœ“
Current ratio rose โ€” โœ• โœ“ โœ“ โœ• โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ“ โ€”
Gross margin rose โ€” โœ• โœ• โœ“ โœ“ โ€”
Revenue rose relative to assets โ€” โœ“ โœ“ โœ• โœ“ โ€”
F-score โ€” / 31 / 93 / 95 / 95 / 9โ€” / 5
Accruals ratio 11.2%6.9%โˆ’20.6%โˆ’20.8%3.9%โˆ’3.5%
Altman Z'' 6.645.731.186.847.46โˆ’0.14

7 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY18FY19FY20FY21FY22FY24FY25
Income statement
Revenue $9.7M $60.7M $64.5M $62.4M $115M โ€” $185M
Provision for credit losses โ€” โ€” โ€” โ€” $0.2M โ€” โ€”
Gross profit $40.4M $36.6M โˆ’$42.0M โˆ’$22.4M $24.8M โ€” $64.5M
Research and development $0.0M $0.3M $0.9M $2.9M $4.7M โ€” $7.8M
Operating income $28.5M $4.1M โˆ’$108M โˆ’$72.4M โˆ’$33.9M โ€” โˆ’$10.9M
Interest expense $7.9M $7.3M $4.5M $2.3M $0.3M โ€” โ€”
Pretax income $21.7M โˆ’$4.4M โˆ’$109M โˆ’$103M โˆ’$11.3M โ€” โˆ’$27.5M
Income tax $4.4M $2.7M โˆ’$7.8M $0.0M โˆ’$0.1M โ€” โˆ’$9.8M
Net income $16.1M โˆ’$7.2M โˆ’$101M โˆ’$103M โˆ’$11.2M โ€” โˆ’$17.7M
Diluted EPS $0.13 โˆ’$0.05 โˆ’$0.59 โˆ’$0.40 โˆ’$0.14 โ€” โˆ’$0.14
Diluted shares 0.13B 0.15B 0.18B 0.26B 0.08B โ€” 0.13B
Cash flow
Cash from operations โˆ’$9.9M โˆ’$26.5M โˆ’$33.5M โˆ’$22.5M โˆ’$28.5M โ€” โˆ’$5.4M
Capital expenditure $44.2M $82.1M $57.4M $9.3M $38.3M โ€” $12.2M
Free cash flow โˆ’$54.1M โˆ’$109M โˆ’$90.9M โˆ’$31.8M โˆ’$66.8M โ€” โˆ’$17.6M
Depreciation and amortization $0.4M $0.5M $1.1M $1.9M $4.2M โ€” $5.5M
Stock-based compensation $3.9M $11.2M $5.8M $3.1M $4.0M โ€” $3.0M
Acquisitions โ€” โ€” โ€” โ€” โ€” โ€” $46.9M
Balance sheet
Cash and short-term investments โ€” โ€” โ€” โ€” โ€” $98.1M $60.0M
Total debt $2.5M $37.3M $88.2M $0.2M $0.2M $0.0M $0.0M
Current assets $156M $148M $130M $207M $169M $194M $205M
Current liabilities $8.6M $33.0M $22.3M $20.9M $42.2M $39.4M $90.6M
Inventory $34.5M $70.1M $50.8M $29.2M $38.4M $49.8M $76.2M
Property and equipment, net $75.6M $164M $189M $187M $198M $71.2M โ€”
Goodwill โ€” โ€” โ€” โ€” โ€” $0.0M $37.7M
Intangible assets $0.0M $1.6M $1.4M $13.5M $42.9M $6.0M $34.8M
Total assets $232M $323M $333M $440M $440M $302M $404M
Total liabilities $90.5M $76.4M $104M $59.0M $52.7M $75.4M $153M
Shareholders' equity $142M $246M $229M $381M $388M $226M $251M
Margins
Gross margin 415.4% 60.3% โˆ’65.1% โˆ’35.9% 21.7% โ€” 34.8%
Operating margin 293.0% 6.8% โˆ’167.6% โˆ’116.0% โˆ’29.6% โ€” โˆ’5.9%
EBITDA margin 297.1% 7.6% โˆ’165.9% โˆ’112.9% โˆ’26.0% โ€” โˆ’2.9%
Net margin 165.0% โˆ’11.9% โˆ’156.9% โˆ’165.1% โˆ’9.8% โ€” โˆ’9.6%
FCF margin โˆ’556.3% โˆ’178.9% โˆ’141.0% โˆ’51.0% โˆ’58.3% โ€” โˆ’9.5%
Returns
Return on capital โ€” โ€” โ€” โ€” โ€” โ€” โˆ’4.5%
Return on capital employed 12.8% 1.4% โˆ’34.8% โˆ’17.3% โˆ’8.5% โ€” โˆ’3.5%
Return on equity 11.3% โˆ’3.7% โˆ’42.6% โˆ’33.7% โˆ’2.9% โ€” โˆ’7.4%
Return on assets 6.9% โˆ’2.6% โˆ’30.9% โˆ’26.6% โˆ’2.6% โ€” โˆ’5.0%
Return on tangible equity 11.3% โˆ’2.9% โˆ’44.4% โˆ’28.0% โˆ’3.3% โ€” โˆ’9.9%
Growth
Revenue growth โ€” 523.4% 6.3% โˆ’3.3% 83.8% โ€” โ€”
Net income growth โ€” โˆ’144.8% โ€” โ€” โ€” โ€” โ€”
EPS growth โ€” โˆ’140.5% โ€” โ€” โ€” โ€” โ€”
Share count change โ€” 19.5% 17.5% 43.8% โˆ’69.8% โ€” โ€”
Financial health
Debt / equity 0.0x 0.2x 0.4x 0.0x 0.0x 0.0x 0.0x
Interest coverage 3.6x 0.6x โˆ’24.2x โˆ’31.0x โˆ’100.6x โ€” โ€”
Current ratio 18.1x 4.5x 5.9x 9.9x 4.0x 4.9x 2.3x
Quick ratio 14.1x 2.4x 3.6x 8.5x 3.1x 3.7x 1.4x
Capital allocation
Capex / revenue 454.1% 135.3% 89.0% 14.9% 33.4% โ€” 6.6%
Stock comp / revenue 40.5% 18.5% 9.0% 4.9% 3.5% โ€” 1.6%
Quality scores
Piotroski F-score โ€” 1.0 3.0 5.0 5.0 โ€” โ€”
Altman Z'' 6.6 5.7 1.2 6.8 7.5 โ€” โˆ’0.1
Accruals ratio 11.2% 6.9% โˆ’20.6% โˆ’20.8% 3.9% โ€” โˆ’3.5%

Source: SEC EDGAR XBRL filings (CIK 0001620737). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in CAD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open